Prakiraan wutah bathi kanggo taun ngarep ghres.com (GHRS)

Logo grafis ghres.com (GHRS)

The dynamics of forward EPS estimates reflect the earnings expectations for GH Research PLC. The biotech firm is developing a unique, ultra-fast inhalational antidepressant with high demand. Intellectual property rights will enable global scaling and massive margins. While the startup currently relies on investment, its patents will provide pricing power. The value of -59.40 determines the latest valuation metric for this asset.

GH Research plc (GHRS): Prakiraan wutah bathi resik saben saham ing taun ngarep saka 04.07.2022 nganti 15.11.2026

GH Research Corp - rincian analitis lan metrik utama (GHRS)

- rega saham lan konsensus proyeksi valuasi:
Pambiji fundamental perusahaan:GHRS, GH Research PLC
Produk dadi GH Research plc

The assessment of the asset's operational resilience is based on an analysis of consensus earnings per share forecasts, where the projected EPS growth rate reflects the business's sensitivity to market shocks and the revaluation of future cash flows. For GH Research PLC (GHRS), with its patented therapies for depression, this metric confirms the ability to capitalize on its monopoly status to drive long-term growth in free cash flow.

Analisis pesaing GH Research PLC